Sign In
Buy PALI
$1.93
+0.0700 (+3.76%)
At Close: Jun 03, 2026
Palisade Bio to Present at the Virtual Investor Pitch Conference
09:15am, Monday, 10'th Jun 2024
Live video webcast on Monday, June 17 th at 12:00 PM ET Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical com
Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local
Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update
08:05am, Tuesday, 14'th May 2024
– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end
Palisade Bio Appoints Margery Fischbein to its Board of Directors
08:30am, Tuesday, 07'th May 2024
Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally
Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
07:30am, Tuesday, 07'th May 2024
Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimm
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
08:30am, Thursday, 02'nd May 2024
Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimm
Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end
Palisade Bio stock rallies on Strand Life Sciences partnership
11:09am, Tuesday, 23'rd Apr 2024
Palisade Bio Inc (NASDAQ: PALI) opened roughly 50% up on Tuesday after teaming up with Strand Life Sciences. Here's what it means for Palisade Bio stock The strategic collaboration puts its patient
Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach
08:30am, Tuesday, 23'rd Apr 2024
– Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics – Partnership marks a significant value-driving milestone in Palisade Bio's mission to redefine UC
Why Is Palisade Bio (PALI) Stock Up 57% Today?
11:22am, Tuesday, 16'th Apr 2024
Palisade Bio (NASDAQ: PALI ) stock is climbing higher on Tuesday after the clinical-stage biopharmaceutical company revealed additional data for its ulcerative colitis (UC) treatment. The big news her
Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”,
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
09:15am, Thursday, 11'th Apr 2024
– Live webcast with members of Palisade Bio management on Tuesday, April 16 th at 12:00 PM ET
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn's & Colitis™
08:15am, Wednesday, 10'th Apr 2024
– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end
Palisade Bio Announces 1-for-15 Reverse Stock Split
05:30pm, Wednesday, 03'rd Apr 2024
Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and a
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
08:35am, Thursday, 15'th Feb 2024
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for ser
